HCA Healthcare, Inc. (NYSE:HCA) is Abrams Bison Investments LLC’s 2nd Largest Position

Abrams Bison Investments LLC trimmed its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 10.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 412,000 shares of the company’s stock after selling 48,000 shares during the period. HCA Healthcare accounts for about 14.5% of Abrams Bison Investments LLC’s investment portfolio, making the stock its 2nd biggest holding. Abrams Bison Investments LLC’s holdings in HCA Healthcare were worth $167,449,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of HCA. Virtu Financial LLC acquired a new position in shares of HCA Healthcare during the 1st quarter worth approximately $537,000. Atria Investments Inc acquired a new stake in shares of HCA Healthcare during the first quarter valued at $1,379,000. Cetera Investment Advisers lifted its holdings in HCA Healthcare by 205.2% in the 1st quarter. Cetera Investment Advisers now owns 18,753 shares of the company’s stock valued at $6,255,000 after purchasing an additional 12,608 shares in the last quarter. Cetera Advisors LLC grew its holdings in shares of HCA Healthcare by 37.3% during the first quarter. Cetera Advisors LLC now owns 7,049 shares of the company’s stock worth $2,351,000 after buying an additional 1,916 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of HCA Healthcare by 45.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 96,506 shares of the company’s stock valued at $31,920,000 after buying an additional 30,139 shares during the period. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Truist Financial increased their price target on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Oppenheimer lifted their price target on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Wells Fargo & Company cut shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and decreased their target price for the stock from $400.00 to $320.00 in a research report on Monday, November 25th. KeyCorp cut their price target on shares of HCA Healthcare from $475.00 to $420.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Finally, Royal Bank of Canada upped their price objective on HCA Healthcare from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $380.29.

Insider Buying and Selling at HCA Healthcare

In other news, SVP Phillip G. Billington sold 3,897 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the transaction, the senior vice president now owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total value of $3,221,340.36. Following the sale, the executive vice president now owns 29,678 shares in the company, valued at $11,438,494.76. The trade was a 21.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,155 shares of company stock valued at $5,608,990 in the last three months. Corporate insiders own 1.60% of the company’s stock.

HCA Healthcare Price Performance

Shares of HCA stock opened at $327.24 on Friday. HCA Healthcare, Inc. has a twelve month low of $246.60 and a twelve month high of $417.14. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The company has a market capitalization of $82.89 billion, a PE ratio of 14.69, a price-to-earnings-growth ratio of 1.25 and a beta of 1.68. The firm has a fifty day simple moving average of $371.88 and a 200-day simple moving average of $358.35.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.66 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.81%. HCA Healthcare’s dividend payout ratio (DPR) is presently 11.85%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.